This page shows the latest talimogene laherparepvec news and features for those working in and with pharma, biotech and healthcare.
year. These are evolocumab for high cholesterol, heart failure drug Corlaner (ivabradine) and talimogene laherparepvec (T-VEC) for melanoma.
The most advanced is Amgen's OncoVex (talimogene laherparepvec), which in 2013 became the first oncolytic virus to show efficacy in a phase III trial involving people with the skin cancer
The early application comes shortly after Amgen filed marketing applications for metastatic melanoma immunotherapy talimogene laherparepvec and PCSK9 inhibitor evolocumab for high cholesterol in both the US and Europe. ... Analysts at JP Morgan have
Amgen submits melanoma and cholesterol drugs to EMA. Regulator will assess talimogene laherparepvec and evolocumab. ... If approved, talimogene laherparepvec will enter what is likely to become a very competitive melanoma market for immunotherapy
for trials with Amgen's talimogene laherparepvec in melanoma, as well as Incyte's INCB24360, an indoleamine 2, 3-dioxygenase inhibitor, in NSCLC.
The latest agreement with Amgen covers the use of MK-3475 alongside oncolytic immunotherapy talimogene laherparepvec in a phase Ib/II study in patients with previously untreated advanced melanoma.